Gyre Therapeutics (GYRE) Cash & Current Investments (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Cash & Current Investments for 17 consecutive years, with $49.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 169.39% year-over-year to $49.8 million; the TTM figure through Mar 2026 stood at $49.8 million (up 169.39% YoY), while the FY2025 annual figure was $40.3 million, up 51.08% from the prior year.
• Cash & Current Investments improved to $49.8 million in Q1 2026 per GYRE's latest filing, from $40.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $75.4 million in Q2 2022 and bottomed at $2.2 million in Q3 2023.
• Historically, Cash & Current Investments has averaged $30.1 million across 5 years, with a median of $25.1 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 90.35% — and 2024, when it jumped 1027.74%.
• Gyre Therapeutics' Cash & Current Investments stood at $23.1 million in 2022, then tumbled by 54.17% to $10.6 million in 2023, then jumped by 151.92% to $26.7 million in 2024, then soared by 51.08% to $40.3 million in 2025, then grew by 23.65% to $49.8 million in 2026.
• Business Quant data shows GYRE's Cash & Current Investments at $49.8 million in Q1 2026, $40.3 million in Q4 2025, and $60.0 million in Q3 2025.